This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immunomedics Awarded Two Additional U.S. Patents For Dock-and-Lock Technology

MORRIS PLAINS, N.J., March 9, 2011 (GLOBE NEWSWIRE) -- Immunomedics , Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that IBC Pharmaceuticals, Inc. (IBC), a majority-owned subsidiary, has received notice that its patent application for "Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology" will issue as U.S. Patent No. 7,906,118 on March 15, 2011.

The 7,906,118 patent covers cytokine-antibody complexes made by the DNL technology.  Cytokines are regulatory proteins, such as interleukins and lymphokines, released by cells of the immune system.  The issued claims cover DNL complexes containing any cytokine attached to any antibody or antibody fragment.  Initial studies with DNL complexes containing four copies of a cytokine per antibody molecule show that the cytokine-antibody DNL complex exhibits greater in vivo efficacy against cancer cells than either cytokine or antibody alone, the unconjugated combination of cytokine and antibody, or a PEGylated form of the cytokine, and has a longer serum half-life than the PEGylated cytokine.

Furthermore, additional claims for the patent family "Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses," will issue as U.S. Patent No. 7,906,121, also on March 15, 2011.  These new patents add to the Company's extensive portfolio of existing DNL patents and further strengthen the patent protection of its proprietary DNL technology. Both patents will expire in March, 2026.

Commenting on the new patent awards, Cynthia L. Sullivan, President and CEO of Immunomedics, said, "We are pleased to receive these new important patents, which cover a new class of agents, such as "20-2b", a DNL construct comprised of 4 interferon-a2b molecules conjugated to veltuzumab, our humanized anti-CD20 antibody in clinical trials. We are currently evaluating this construct as a potential new therapy for patients with CD20-expressing lymphomas, funded by a new grant from the National Cancer Institute's Small Business Innovation Research program."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.24 1.30%
FB $99.75 -4.15%
GOOG $683.10 -0.07%
TSLA $147.99 -8.99%
YHOO $27.05 -3.30%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs